Cussen resigns from Eiffel
05 May, 2005 by Renate KrelleChristine Cussen has resigned from her role as chief executive of drug re-engineering company Eiffel (ASX:EIF), at a time when the company's share price has dipped below $0.04 - more than two thirds below its level in January of around $0.12.
Axon, C3 alumni among Clunies Ross winners
03 May, 2005 by Ruth BeranBioscience entrepreneurs, including Axon Instruments founder Alan Finkel and Fiona Wood and Marie Stoner of Clinical Cell Culture, have dominated the winners' circle at this year's ATSE Clunies Ross Awards.
US ponders loosening NIH ethics rules
29 April, 2005 by Staff WritersStrict new ethics rules imposed on National Institutes of Health staff to prevent lucrative deals with drug companies may be loosened if warranted, Health and Human Services Secretary Mike Leavitt has said.
Sydney scientist develops new hearing software
29 April, 2005 by Susan WilliamsonA University of Sydney scientist has developed a software algorithm which improves the ability of the hearing-impaired to hear in noisy environments.
Swiss biotechs squeeze through as European IPO window closes
28 April, 2005 by Staff WritersTwo Swiss drug developers have set out their stalls this month to test the market's remaining appetite for biotechnology IPOs, buoyed by the success of Swiss rivals and renewed investor interest in the battered drugs sector.
Govt concern prompts audit of science skills shortage
26 April, 2005 by Graeme O'NeillThe federal government has released a discussion paper on Australia's growing shortage of skilled professionals in science, engineering and technology (SET).
Q1 results: Serono, Schering, Affymetrix, Chugai, Shire
26 April, 2005 by Staff WritersShares in Swiss biotechnology company Serono have tumbled after the firm unexpectedly booked US$725 million to cover legal costs relating to an investigation into US sales of its Serostim AIDS drug.
Universities combine forces to form new meditech
26 April, 2005 by Graeme O'NeillIn a rare example of cross-pollination, the University of Sydney and the University of Western Sydney have pooled the IP from three advanced research projects on inflammation and cancer, and spun out a new biomedical company, Medical Therapies.
Optiscan claims good results from Pentax partnership
21 April, 2005 by Graeme O'NeillThe 25,000 doctors attending the world's largest gastroenterology meeting in Chicago next month will be briefed about a revolution in the detection and diagnosis of gastrointestinal diseases, engineered by Melbourne's Optiscan (ASX:OIL) and its giant Japanese partner Pentax.
In brief: Select Vaccines, Psiron, Visiomed
21 April, 2005 by Graeme O'NeillSelect Vaccines' (ASX:SLT) hepatitis E diagnostics kits have gained CE Mark approval for sale in the European Union. The company will sell the kits from June this year through its licencee, Genelabs
Q4 profits: Wyeth; Biocon
21 April, 2005 by Staff WritersWyeth's first-quarter earnings have risen 44 percent as sales of its vaccine against childhood infections more than doubled and sales of arthritis treatment Enbrel and other prescription drugs rose.
Beattie announces $473m funding boost
19 April, 2005 by Graeme O'NeillQueensland's Beattie Government has announced AUD$473 million in new funding for the second phase of its Smart State Strategy.
Invest in basic science to reap rewards: expert
14 April, 2005 by Staff WritersMark Crowell -- a leading US technology-transfer expert -- has a message for Australian universities wanting to make money out of research: it is vital that the public sector continue funding good, basic science to drive the knowledge economy.
Vic govt announces $57m in infrastructure grants
14 April, 2005 by Renate KrelleA tissue engineering centre, a tumour tissue banking facility and a biopharmaceutical formulation facility are three of 17 projects that will share a total of $57 million in major infrastructure grants, announced today by the Victorian government.
Australians publishing more, but not patenting: report
13 April, 2005 by Renate KrelleAlthough government and higher education R&D expenditure are on the up, and Australia generated almost 50 per cent more scientific and technical articles in 2003 than in 1999, the number of US patents granted to Australia has fallen, a government report has revealed.
